Avivagen Inc. (TSX-V: VIV, OTC Pink: CHEXF), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announced at the Corporation's annual and special meeting of shareholders (AGM) held yesterday that the shareholders voted to support the resolutions proposed by the Corporation. The resolutions and the voting results included the following:
The Corporation is pleased to have Mr. Jeffrey Kraws join the Board of Directors. Mr. Kraws is a co-founder and Chief Executive Officer of Crystal Research Associates, a firm established in 2003 in response to the growing need for independent equity research and innovative thinking in today's highly competitive markets. Mr. Kraws has received some of the most prestigious awards in the industry, including being consistently ranked among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates by Zacks. Additionally, Mr. Kraws has been 5-Star-ranked for top biotechnology stock performance by Starmine.
Mr. Kraws is currently chairman of Synthetic Biologics Inc., a NYSE-listed biotechnology company, and a partner and co-founder of TopHat Capital, LLC. He is also the President of Ra Medical, a medical device company commercializing breakthrough laser therapies for a number of dermatology and vascular diseases. He also serves as a director of Saleen Automotive. Through his years of experience, Mr. Kraws has cultivated a wealth of industry knowledge and a level of credible, insightful equity analysis that few share. As a result, he has provided guest commentary for many network news programs, including Bloomberg, FOX Business, and CNBC, among others, and has become a valuable resource for financial journalists from the New York Times, Forbes, Bloomberg, CBS MarketWatch, and MedAdNews, among other publications. Mr. Kraws holds an MBA from Cornell University and a B.S. from the State University of New York-Buffalo.
Avivagen Remains Focused on Gaining Market Approval of OxC-beta™ in Multiple Geographies
At the AGM, the Chair of the Board of Directors and Interim CEO, Mr. Kym Anthony, indicated that the Corporation was continuing to pursue the following key initiatives:
Avivagen Inc. is a public company traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com .